Slide 1: Cover letter to stock exchanges - Investor Presentation
25th July, 2025 (1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Scrip Code: 500087 Bandra (East), Mumbai - 400 051 Scrip Code: CI
Slide 2: Investor Presentation Q1FY26
Investor Presentation Q1FY26 25-07-2025 1
Slide 3: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 4: Profitability Momentum Continues with Strong EBITDA Margin at 25.6%
Profitability Momentum Continues with Strong EBITDA Margin at 25.6% Revenue EBITDA PAT 4% INR 1,778 Cr 4% (YoY) INR 1,298 Cr 10% (YoY) Q1FY26 INR 6,957 Cr (YoY) 25.6% 18.7% of Revenue of Revenue Business Performance Snapshot Emerging Markets & One India North America One Africa Europe INR 3,070 Cr 6
Slide 5: Financial Performance – Q1FY26
Financial Performance – Q1FY26 Revenues INR 6,957 Cr EBITDA INR 1,778 Cr Revenue1 Break-up Q1FY26 (Consolidated) API, 1% Others, 2% Actuals vs Q1 FY25 Emerging Markets & (INR Cr) Europe, 12% Total Revenue from 6,957 3.9% Operations EBITDA 1,778 3.6% One Africa, One India, 13% 44% EBITDA % 25.6% -7 b
Slide 6: One India - Committed to Sustainable Progress and Enduring Impact
One India1 - Committed to Sustainable Progress and Enduring Impact One India revenue trend Highest ever Q1 Sales Q1FY26 Revenue Crossed the threshold INR 3,000+ Cr for the first time ever INR 3,070 Cr in the opening quarter of any financial year Branded Prescription Trade Generics Consumer Health ❖
Slide 7: India Rx - Strengthening Our Journey with Strategic Therapeutic Focus
India Rx - Strengthening Our Journey with Strategic Therapeutic Focus Steady uptake in key therapies1 growth (%) 5% (13%)2 Slow industry Respiratory 6% (16%)2 Largest pharma company by volume growth in (12%)2 Respiratory and (units) in market1 Anti-infectives 5% 8% (13%)2 Anti-infectives 13% 5 brand
Slide 8: One India: Accelerating Innovative Portfolio in Respiratory and Other Chronic Therapies
One India : Accelerating Innovative Portfolio in Respiratory and Other CLICK Chronic TO EDIT MASTER TITLE STYLE Therapies Respiratory Other Chronic Therapies ❑ Launched Empa and achieved Anti-Diabetes 4th rank amongst new players post LOE launch ❑ Strengthened presence through Strategic Restructurin
Slide 9: Q1 FY26 - Global Consumer Wellness Franchise
Q1 FY26 - Global Consumer Wellness Franchise One India One Africa Consumer brands in 2 One India 2 Revenue: INR 470 Cr Pain Relief Hydration Cold &Cough Cold & Cough 1 2 Nicotine Consumer brands in INR 141C`r Skin Infection South Africa Pain Replacement Respi OTC Management 2 Revenue: ZAR 358 Mn Col
Slide 10: North America - Witnessed Continuous Traction in Key Differentiated Assets
North America - Witnessed Continuous Traction in Key Differentiated Assets Key Product launches Nilotinib Capsules - Nano Paclitaxel - 100 50, 150 and 200 mg mg/vial (ANDA) (NDA) Key Business Highlights • Albuterol ranked No. 1 in the market1 (50 million+ inhaler units supplied to the U.S. market cu
Slide 11: ANDA & NDA Portfolio & Pipeline (As on 30th Jun 2025)
ANDA & NDA Portfolio & Pipeline (As on 30th Jun 2025) 9 66 9 2 15 94 2 4 1 22 44 14 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs Cipla Ltd PEPFAR 1 Invagen Partnered ANDAs/NDAs 178 39 65 282 Approved Tentatively Under Approval Total ANDAs & NDAs Approved ANDAs
Slide 12: One Africa - South Africa Private Growing 1.5x Faster than the Market
One Africa1 - South Africa Private Growing 1.5x Faster than the Market ZAR Mn $ Mn SA Private Revenue trend 12 8 9 8 19 23 1,044 1,063 939 56 59 Q1FY25 Q1FY26 Q1FY24 Q1FY25 Q1FY26 SA Private SA Tender North Africa Others (SSA & CGA) Market Segment2 Rank Share Cipla Growth Market Growth SA Key Highli
Slide 13: Q1FY26 - Emerging Markets & Europe and API
Q1FY26 - Emerging Markets & Europe and API Emerging Markets & Europe API $ Mn Revenue $ Mn Revenue 101 12 12 93 Q1FY25 Q1FY26 Q1FY25 Q1FY26 12
Slide 14: Progress on ESG Goals (India Manufacturing Operations) - FY25
Progress on ESG Goals (India Manufacturing Operations) - FY25 CLICK TO EDIT MASTER TITLE STYLE Goals (India manufacturing operations) Progress as on 31st March 2025 80% reduction in absolute Scope 1 (energy based) and 58% reduction from the baseline year, FY 2019-20 Scope 2 emissions* Water neutrali
Slide 15: Consolidated Profit and Loss
Consolidated Profit and Loss INR Cr Particulars Q1 FY26 Q1 FY25 Revenue from sale of products 6,837 6,625 Other operating income 120 69 Income from operations 6,957 6,694 Material cost 2,171 2,193 Employee benefits expense 1,312 1,194 Other expenses 1,696 1,591 Total expenses 5,179 4,978 Finance cos
Slide 16: Consolidated Balance Sheet
Consolidated Balance Sheet Key Balance Sheet Items Jun-25 Jun-24 INR Cr Equity 32,665 28,058 Total Debt# 459 547 Inventory 6,091 5,531 Cash and Cash Equivalents* 10,838 8,996 Trade Receivables 6,254 4,989 Trade Payables 3,093 2,742 Net Tangible Assets 6,669 6,210 Goodwill and Intangibles 5,138 4,941
Slide 17: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.cipla.com 16